Eli Lilly and Company (NYSE:LLY) investors who chased the stock toward its July/August 2024 highs have likely been stunned ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion ...

New Barcelona site to help drive global expansion of QIAstat-Dx as QIAGEN expands local presence with multi-year investment ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

Eli Lilly and Company chief corporate brand officer Lina Polimeni described the new format as a “big evolution” in the ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...